Holen Sie sich die Stockscreener-App
76.28
5.87%
-4.76
Handel nachbörslich:
76.28
Ani Pharmaceuticals Inc Aktie (ANIP) Neueste Nachrichten
ANI Pharmaceuticals (NASDAQ:ANIP) Trading Down 6.3%Time to Sell? - MarketBeat
Momentum Shift: How ANI Pharmaceuticals Inc. stock performs in weak economyTrade Entry Summary & High Return Trade Guides - ulpravda.ru
How ANI Pharmaceuticals Inc. stock reacts to global recession fears2025 Growth vs Value & Reliable Breakout Stock Forecasts - ulpravda.ru
Is ANI Pharmaceuticals Inc. (BSFA) stock a defensive play amid uncertainty2025 EndofYear Setup & Expert Verified Stock Movement Alerts - ulpravda.ru
How ANI Pharmaceuticals Inc. stock performs in weak economyWeekly Stock Summary & Risk Adjusted Buy/Sell Alerts - ulpravda.ru
What earnings margins imply for ANI Pharmaceuticals Inc. (BSFA) stockJuly 2025 Spike Watch & Consistent Return Investment Signals - ulpravda.ru
ANI Pharmaceuticals (NASDAQ:ANIP) Lowered to "Hold" Rating by Zacks Research - MarketBeat
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Nasdaq Today Specialty Pharma Focus - Kalkine Media
Is ANI Pharmaceuticals (ANIP) Price Justified After Updated 2025 Revenue Guidance? - Yahoo Finance
ANI Pharmaceuticals, Inc. CEO Nikhil Lalwani to Present at 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative
ANI Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
ANIP Up 21% in 6 Months: Is It Worth Investing in the Stock Now? - Your Wyoming Link
ANI Pharmaceuticals, Inc. (ANIP) Stock Analysis: A Healthcare Gem with 38.89% Upside Potential - DirectorsTalk Interviews
3 Reasons to Avoid ANIP and 1 Stock to Buy Instead - Finviz
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q4 2024 Earnings Call Transcript - MSN
2025’s best-performing Minnesota public company stock is a biopharmaceutical firm with no revenue - Star Tribune
Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Revenue per share of ANI Pharmaceuticals, Inc. – MUN:BSFA - TradingView — Track All Markets
ANI Stock Is Up 49% This Past Year, Revenue Is Surging, and One Fund Still Walked Away - The Globe and Mail
ANI Stock Is Up 49% This Past Year, Revenue Is Surging, and One Fund Still Walked Away - The Motley Fool
ANI Pharmaceuticals, Inc. $ANIP Shares Sold by Rice Hall James & Associates LLC - MarketBeat
Assessing ANI Pharmaceuticals (ANIP) Valuation After a Strong Yearly Share Price Rally - Yahoo Finance
ANI Pharma stock pullback tied to Cortrophin guidance uncertainty - Investing.com
ANI Pharmaceuticals, Inc. $ANIP Shares Purchased by Assenagon Asset Management S.A. - MarketBeat
ANI Pharmaceuticals (NASDAQ:ANIP) Trading Down 3.6% on Insider Selling - MarketBeat
ANI Pharmaceuticals to Report Q1 Earnings: Is a Beat in the Cards? - MSN
Will ANI Pharmaceuticals Inc. stock attract ESG investorsMarket Trend Summary & AI Powered Market Entry Ideas - Улправда
ANI Pharmaceuticals (NASDAQ:ANIP) SVP Sells $133,652.80 in Stock - MarketBeat
ANI Pharmaceuticals Executive Sells Shares - TradingView — Track All Markets
VP Davis Sells 1,622 ($133.7K) Of ANI Pharmaceuticals Inc [ANIP] - TradingView — Track All Markets
Squarepoint Ops LLC Takes $2.14 Million Position in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Can ANI Pharmaceuticals Inc. stock rebound after recent weaknessQuarterly Trade Review & Daily Oversold Bounce Ideas - DonanımHaber
Is ANI Pharmaceuticals Inc. stock trading at a premium valuationWeekly Gains Summary & Weekly Watchlist for Hot Stocks - Улправда
Can ANI Pharmaceuticals Inc. stock deliver consistent earnings growthJuly 2025 Recap & Safe Capital Growth Tips - Улправда
ANI Pharmaceuticals (ANIP): Assessing Valuation After Recent Share Price Momentum - Sahm
Zacks Industry Outlook Arcutis, Amicus and ANI - The Globe and Mail
Why ANI Pharmaceuticals Inc. stock attracts high net worth investorsJuly 2025 Chart Watch & Fast Gaining Stock Reports - Улправда
FDA Grants Fast Track Designation to ADAG's Colorectal Cancer Drug - Finviz
Is ANI Pharmaceuticals Stock Price Justified After 47% 2025 Rally? - Yahoo Finance
How Investors May Respond To ANI Pharmaceuticals (ANIP) Creating a Retina-Focused FutureVision Advisory Council - Yahoo Finance
Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year? - Yahoo Finance
Ranger Investment Management L.P. Reduces Stock Holdings in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Implied volatility surging for ANI Pharmaceuticals stock options - MSN
ANI Pharmaceuticals (NASDAQ:ANIP) VP Sells $32,928.00 in Stock - MarketBeat
ANI Pharmaceuticals Senior VP Meredith Cook Sells 400 Shares - TradingView — Track All Markets
ANI Pharmaceuticals (ANIP) officer Meredith Cook sells 400 shares via 10b5-1 plan - Stock Titan
ANI Pharmaceuticals price target raised to $115 from $114 at Guggenheim - MSN
ANI Pharmaceuticals (ANIP): Assessing Valuation After a Strong Year and Recent Share Price Pullback - Sahm
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
ANI Pharmaceuticals to Report Q3 Earnings: Is a Beat in the Cards? - MSN
Implied Volatility Surging for ANI Pharmaceuticals Stock Options - Nasdaq
ANI Pharmaceuticals Completes Mandatory Conversion of Preferred Shares - MSN
ANI Pharmaceuticals Director Sold $146K In Company Stock - Benzinga
ANI Pharmaceuticals (NASDAQ:ANIP) Director Sells $146,070.00 in Stock - MarketBeat
ANI Pharmaceuticals Director Sells 1,800 Shares - TradingView — Track All Markets
ANI Pharmaceuticals (NASDAQ:ANIP) Coverage Initiated by Analysts at Barclays - MarketBeat
Barclays Initiates ANI Pharmaceuticals at Overweight With $100 Price Target - marketscreener.com
ANI Pharmaceuticals chairman Patrick Walsh to retire, Thomas Haughey to succeed - MSN
0.37%
1.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):